Trial Profile
A Randomized, Open Label, Four Period, Four Sequence, Single Dose, Crossover Study to Evaluate Relative Bioavailability of K0706 24 mg Tablet Formulation Relative to 24 mg Capsule Formulation Under Fasted Conditions and to Evaluate the Food Effect for Tablet Formulation in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Oct 2018
Price :
$35
*
At a glance
- Drugs Vodobatinib (Primary)
- Indications Chronic myeloid leukaemia; Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Sun Pharma Advanced Research Company
- 26 Jan 2018 Status changed from not yet recruiting to completed.
- 25 Oct 2017 New trial record